Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis

By sjmartinez • December 2, 2024

Cumpian NA, Choi G, Saab S. Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis. Dig Dis Sci. 2024 Dec 2. doi: 10.1007/s10620-024-08742-w. Epub ahead of print. PMID: 39621183.

Tags: ALP, Bezafibrate, Digestive Diseases, Elafibranor, General Internal Medicine, Harbor UCLA, OCA, PBC, Publications, Resident, second-line, Seladelpar, UDCA

Related Posts

Corrigendum to “Subchronic inhalation exposure to ultrafine particulate matter alters the intestinal microbiome in various mouse models” [Environ. Res. 248 (2024) 118242]

Chang C, Gupta R, Sedighian F, Louie A, Gonzalez DM, Le C, Cho JM, Park SK, Castellanos J, Ting TW, Dong TS, Arias-Jayo N, Lagishetty[...]

Effectiveness of transoral endoscopic fundoplication with or without hiatal hernia repair in patients with gerd and chronic cough

Swei E, Almario JA, Dunbar K, Yadlapati R, Parker B, Brewer-Gutierrez O, Janu P, Murray M, Sohagia A, Diehl DL, Khara H, Abu Dayyeh B,[...]

Identification of a PRDM1-regulated T cell network to regulate atherosclerotic plaque inflammation

Jin H, Maas SL, Zou Y, Lu C, Yu B, Huchzermeier R, Nadeau S, Dos Santos J, Gijbels M, Mees BME, Smirnov E, Matic L,[...]